&nbsp;

Jan 2025

Drug

daSATinib

Other Name(s): Sprycel®

Quick Link(s):

Feb 2025

Drug

degarelix

Other Name(s): Firmagon®

Quick Link(s):

Feb 2025

Drug

lorlatinib

Other Name(s): Lorbrena®

Quick Link(s):

Feb 2025

Drug

decitabine / cedazuridine

Other Name(s): Inqovi®

Quick Link(s):

Feb 2025

Drug

tucatinib

Other Name(s): Tukysa™

Quick Link(s):

Feb 2025

Drug

dostarlimab

Other Name(s): Jemperli

Quick Link(s):

Feb 2025

Drug

nivolumab / relatlimab

Other Name(s): Opdualag™

Quick Link(s):

Feb 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

daSAtinib - Ph+ CML in the chronic phase, with specific criteria

Exceptional Access Program

daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria

, Collapse Show fewer tags

Drugs Used:

daSATinib

... Show more tags

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DGRL

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Palliative

Funding:

ODB - General Benefit

degarelix

, Collapse Show fewer tags

Drugs Used:

degarelix

... Show more tags

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

DASA

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative, Palliative

Funding:

Exceptional Access Program

daSAtinib - PH+ ALL, with specific criteria